patient-reported tolerability

Immunotherapy and antibody drug conjugates are quickly becoming the backbone of treatment regimens for breast cancer. However, these therapies do present with appreciable treatment emergent adverse events that are variable and difficult to predict in individual patients. Patient reported outcomes (PROs) are critical for understanding the patient experience and kinetics of treatment emergent adverse event. Therefore, providing tools for patients…

This study aimed to adopt this novel method to explore PRT in breast cancer using PROs collected in real-world clinical practice.

This study aimed to adopt this novel methodology to explore PRT in patients with MM using PROs collected in real-world clinical practice.